Abstract
Ekeke and colleagues1 present an interesting report in which they develop a malignant pleural effusion model with Lewis lung cancer cells in mice with direct pleural injections of recombinant interleukin (IL) 2 on a vaccinia backbone. They found that direct administration of IL-2 to the pleural resulted in lower tumor burden and longer survival compared with systemic administration of IL-2. Next, they asked whether systemic programmed cell death protein (PD) 1 inhibition would augment the effects of intrapleural IL-2.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Thoracic and Cardiovascular Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
